TESARO Inc

Type: Company
Name: TESARO Inc
Nationality: United States
Web Address: http://tesarobio.com/
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Business Digest for July 11, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. Boston Organ and Piano sells for $3M After 40 years under the same ownership, the iconic Boston Organ and Piano building on Rte. 9 in Natick has changed hands. Ria K. McNamara, ... [Published Wicked Local Foxborough - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Myriad Genetics Poised on Strong Fundamentals

On July 9, we issued an updated research report on leading molecular diagnostic company Myriad Genetics Inc. ( MYGN ). While we are impressed with the company’s strong fundamentals, as once again reflected in the last reported quarter’s financial performance, ... [Published Yahoo! Finance - Jul 10 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 3 reports

TESARO to Announce Second-Quarter 2014 Financial Results on July 24, 2014

(GLOBE NEWSWIRE) -- TESAROThe quarterly earnings call will be available via phone and webcast. The conference call dial-in information is listed below. To access the webcast, please log on to the TESARO website at www.tesarobio.comAbout TESAROTESARO, ... [Published BusinessWeek - Jul 10 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 1 reports

3 Big Stocks on Traders' Radars

BALTIMORE (Stockpickr) -- Put down the 10-K filings and the stock screeners. It's time to take a break from the traditional methods of generating investment ideas. Instead, let the crowd do it for you. >>5 Rocket Stocks to Buy for Earnings Sea ... [Published The Street Latest - Jul 09 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Commit To Purchase Tesaro At $25, Earn 14.2%...

Investors eyeing a purchase of Tesaro Inc (Symbol: TSRO) stock, but tentative about paying the going market price of $33.13/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract ... [Published Nasdaq - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 02 2014 - 1 reports

TSRO Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of Tesaro Inc (TSRO) crossed above their 200 day moving average of $32.35, changing hands as high as $34.30 per share. Tesaro Inc shares are currently trading up about 9.9% on the day.. ... [Published Tamar Securities - Jul 01 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher

(TSRO) was a big mover last session with shares rising nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company, as the stock has gained nearly ... [Published Yahoo! Finance - Jul 02 2014]
First reported Jun 27 2014 - Updated Jun 27 2014 - 1 reports

TESARO Summarizes Rolapitant Data Presented at the 2014 MASCC/ISOO International Symposium on Supportive Care in Cancer

MIAMI, June 27, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. ( Nasdaq:TSRO ), an oncology-focused biopharmaceutical company, today announced that three oral presentations detailing the final results from the rolapitant registration program were delivered today ... [Published Franklin Credit Management Corporation - Jun 27 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

Short Interest In Tesaro Increases 13.7%

at 16:07 PM EDT The most recent short interest data has been released by the NASDAQ for the 06/13/2014 settlement date, which shows a 286,428 share increase in total short interest for Tesaro Inc (TSRO), to 2,373,750, an increase of 13.72% since 05/30/2014. ... [Published Fat Pitch Financials - Jun 25 2014]
First reported Jun 20 2014 - Updated Jun 21 2014 - 1 reports

OPKO CEO Is Building A Pharma Powerhouse And Continuously Buying Shares

OPKO Health ( OPK ) has come to my attention because I noticed that the chairman and CEO, Dr. Phillip Frost , has been consistently showing up on the list of CEO buys at GuruFocus. As I look back at the history, he has been doing so for years. According ... [Published Guru Focus - Jun 20 2014]
First reported Jun 18 2014 - Updated Jun 18 2014 - 1 reports

Busins Digest for June 18, 2014

SeaChange appoints Fitzgerald senior VP SeaChange International Inc., an Acton-based global multi-screen video software company, recently appointed global television technology sales veteran Ray Fitzgerald of Illinois to senior vice president of sales ... [Published Wicked Local Hopkinton - Jun 18 2014]
First reported Jun 13 2014 - Updated Jun 13 2014 - 1 reports

Futures Point To Higher Open, S&P 500 Near Record

ListenNEW YORK:U.S. stock index futures pointed to a higher open on Monday, putting the S&P 500 within striking distance of record levels, though geopolitical concerns in the Ukraine could cap gains.* In Ukraine, pro-Russian rebels voted in favor of self-rule ... [Published Gulf Time UAE - Jun 13 2014]

Quotes

"NSCLC is an area that no other PARP inhibitor has explored [and] we are able to go there because we found a way to successfully combine with carboplatin-based chemotherapy" he said in a recent investor presentation. That "broadens our opportunity for veliparib as a consequence," added Brun
...failed R&D efforts may make AstraZeneca shareholders more inclined to push AstraZeneca into Pfizer's arms," said Bernstein analyst Tim Anderson. "Every bit of slippage at the company probably does tilt the balance slightly more in favour of a future Pfizer-AstraZeneca tie-up."
...strong demand for Protein A affinity ligands and our OPUS pre-packed chromatography columns," said Walter C Herlihy, president and CEO of Repligen. "The combination of robust sales growth, higher gross margins and a lower tax rate positively impacted the first quarter results for our bioprocessing business, enabling the company to deliver improved earnings despite a decrease in royalty and other revenue." For more information, visit repligen.com
"The rolapitant arm in this trial, which enrolled patients receiving cisplatin-based, highly emetogenic chemotherapy, (HEC) successfully achieved statistical significance over the standard therapy arm for the primary and all secondary endpoints" the company said in a statement

More Content

All (73) | News (40) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (21)
sort by: Date | Relevance
Business Digest for July 11, 2014 [Published Wicked Local Foxborough - Jul 11 2014]
Myriad Genetics Poised on Strong Fundamentals [Published Yahoo! Finance - Jul 10 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published GlobeNewswire: Advertising News - Jul 10 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published BusinessWeek - Jul 10 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published Stock Nod - Jul 10 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published Crawford Financial Planning - Jul 10 2014]
3 Big Stocks on Traders' Radars [Published The Street Latest - Jul 09 2014]
'Fast Money' Recap: Waiting for the Dust to Settle [Published TheStreet.com - Jul 09 2014]
'Fast Money' Recap: Waiting for the Dust to Settle [Published The Street Latest - Jul 09 2014]
Commit To Purchase Tesaro At $25, Earn 14.2%... [Published Nasdaq - Jul 03 2014]
Tesaro (TSRO) in Focus: Stock Moves 8.9% Higher [Published Yahoo! Finance - Jul 02 2014]
Market Expansion, Merger Agreements, Management... [Published Financial Services - Jul 02 2014]
TSRO Makes Bullish Cross Above Critical Moving ... [Published Tamar Securities - Jul 01 2014]
Bristol-Myers Receives Positive CHMP Opinion fo... [Published BioMedReports - Jun 29 2014]
TESARO Summarizes Rolapitant Data Presented at ... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
TESARO Summarizes Rolapitant Data Presented at ... [Published Franklin Credit Management Corporation - Jun 27 2014]
AbbVie takes PARP inhibitor into third phase II... [Published PMLive - Jun 27 2014]
Cancer drug setback tarnishes AstraZeneca's R&D... [Published Yahoo! Finance - Jun 26 2014]
Short Interest In Tesaro Increases 13.7% [Published Fat Pitch Financials - Jun 25 2014]
OPKO CEO Is Building A Pharma Powerhouse And Co... [Published Guru Focus - Jun 20 2014]
Busins Digest for June 18, 2014 [Published Wicked Local Hopkinton - Jun 18 2014]
Futures Point To Higher Open, S&P 500 Near Record [Published Gulf Time UAE - Jun 13 2014]
Business digest for June 12 [Published MetroWest Daily News - Jun 12 2014]
TESARO Inc: Immunotherapy Pipeline In progress [Published Investing.com - Jun 11 2014]
Business Digest for June 10, 2014 [Published Wicked Local Boston - Jun 10 2014]
Tesaro Summarizes Phase 3 Rolapitant Data Prese... [Published GlobeNewswire: Advertising News - Jun 02 2014]
TESARO Appoints Tim Pearson as Chief Financial ... [Published GlobeNewswire: Acquisitions News - May 27 2014]
TESARO Announces Webcast of Investor & Analyst ... [Published GlobeNewswire: Acquisitions News - May 27 2014]
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
TESARO Announces Election of Earl M. (Duke) Col... [Published GlobeNewswire: Acquisitions News - May 16 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
BOSTON--(BUSINESS WIRE)--More than 200 leading CEOs from the biotechnology community will gather at the 2014 Boston CEO Conference June 4th and 5th at the Four Seasons Hotel in Boston. Past award winners Henri Termeer, Josh Boger, Deborah Dunsire and ...
Clinical Trial Updates, Leadership Appointments... [Published PR Newswire: Financial Services - May 15 2014]
NEW YORK, May 15, 2014 /PRNewswire/ --Today, Analysts Review released its analysts' notes regarding Tesaro, Inc. (NASDAQ: TSRO), Novavax, Inc. (NASDAQ: NVAX), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Insmed Incorporated (NASDAQ: INSM) and Durata Therapeutics, ...
OPKO Licensee TESARO Announces Successful Achie... [Published Business Wire Health News - May 12 2014]
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK), reported that its licensee, TESARO, Inc. (Nasdaq:TSRO), announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist ...
Tesaro's nausea drug meets main goal in final t... [Published Yahoo! Health News - May 12 2014]
(Reuters) - Tesaro Inc said its drug for the prevention of chemotherapy-induced nausea and vomiting met the main goal in a third late-stage trial. Tesaro shares jumped nearly 15 percent to $27.51 in premarket trading, after the company said the d... ...
Frontrunning: May 1 [Published Zero Hedge - May 01 2014]
Two-Thirds of Insurance Exchange Enrollees Paid Premiums ( WSJ ) Panic: Criminal Charges Against Banks Risk Sparking Crisis ( BBG ) Did the junk bubble pop: Junk Loans Pulled as Investors Say No After Fed Raises Concerns ( BBG ) CME mulls price fluctuation ...
1 2 3

Press Releases

sort by: Date | Relevance
TESARO to Announce Second-Quarter 2014 Financia... [Published GlobeNewswire: Advertising News - Jul 10 2014]
Market Expansion, Merger Agreements, Management... [Published Financial Services - Jul 02 2014]
TESARO Summarizes Rolapitant Data Presented at ... [Published GlobeNewswire: Acquisitions News - Jun 27 2014]
Tesaro Summarizes Phase 3 Rolapitant Data Prese... [Published GlobeNewswire: Advertising News - Jun 02 2014]
TESARO Appoints Tim Pearson as Chief Financial ... [Published GlobeNewswire: Acquisitions News - May 27 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.